Year: 2010
Type: article
Study design: Case Report
Abstract: 34-year-old Caucasian male. Pathologist’s review of peripheral smear is requested secondary to presence of circulating blasts. The patient has a 7-year history of Crohn’s disease. He has been treated with Natalizumab (Tysabri) since April 2008, after infliximab and high-dose steroids failed to control his symptoms. He stated he has an average of 5–7 bowel movements daily. He denies changes in the number of bowel movements, hematochezia, abdominal pain, fatigue, night sweats, fever/chills, weight loss, or neurologic symptoms, including visual changes, changes in thought process, or headaches. He also denies recent travel or recent illness. Crohn’s disease diagnosed in 2003, status post partial small bowel resection and multiple stricturoplasties. Well documented iron deficiency anemia. Natalizumab; 300 mg IV every 4 weeks and iron infusions; monthly. Non-contributory. Vital signs: blood pressure, 143/92 mmHg; temperature, 36.1°C; pulse, 81 bpm; respirations, 14. HEENT: Conjunctivae are clear. Sclerae are anicteric. Oropharynx is clear. There is no lymphadenopathy. Abdomen: Active bowel sounds, soft and nontender, no hepatosplenomegaly or masses.
Source: Laboratory Medicine
Institution: University of North Carolina at Chapel Hill
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2117165152